Furosemide Should NOT Be Used in Infants with Patent Ductus Arteriosus
Furosemide is contraindicated in the management of PDA in premature infants, as it increases the risk of persistent PDA and causes significant renal toxicity without providing benefit.
The Evidence Against Furosemide in PDA
FDA Warning on PDA Risk
The FDA drug label explicitly warns that in premature neonates with respiratory distress syndrome, furosemide treatment in the first few weeks of life may increase the risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin-E-mediated process 1. This is a direct contraindication for using furosemide when PDA is a concern.
Mechanism of Harm
Furosemide stimulates renal prostaglandin E2 synthesis, which is a potent dilator of the ductus arteriosus. A landmark study demonstrated that furosemide significantly increased PDA incidence (18 of 33 infants, 55%) compared to chlorothiazide (8 of 33 infants, 24%; P < 0.02) 2. After the fifth day of life, prostaglandin E excretion tripled after furosemide administration, directly promoting ductal patency.
Lack of Benefit When Combined with Indomethacin
When furosemide is given alongside indomethacin (the standard medical treatment for PDA):
- No improvement in ductal closure rates: Systematic reviews found no significant difference in PDA closure between furosemide-treated and control groups 3, 4
- Does not prevent indomethacin toxicity: The theoretical benefit of reducing indomethacin's renal side effects was not realized
Significant Renal Toxicity
Multiple studies demonstrate that furosemide actually worsens renal function in infants receiving indomethacin:
- Increased acute renal failure: 59% (20/34) of furosemide-treated infants developed ARF (creatinine >1.6 mg/dl) versus only 10% (3/29) of controls (P < 0.001) 5
- Elevated serum creatinine: 50% increase in the furosemide group versus 18% in controls at 72-96 hours (P < 0.05) 6
- Severe hyponatremia: Serum sodium decreased by 9 mmol/L in furosemide group versus 3 mmol/L in controls (P < 0.05) 6
- No improvement in urine output: Despite theoretical diuretic effects, day-to-day urine output changes were not different between groups 6
Dehydration Risk
Furosemide causes approximately 5% weight loss during a 3-dose indomethacin course, which is particularly harmful in infants with elevated BUN/creatinine ratios (>20 mg/mg) indicating pre-existing dehydration 3, 4. Furosemide is explicitly contraindicated in dehydrated infants receiving indomethacin for PDA.
Clinical Algorithm for PDA Management
When managing PDA in premature infants:
- Avoid furosemide entirely - it promotes ductal patency and causes renal harm
- Use cyclooxygenase inhibitors (indomethacin, ibuprofen, or acetaminophen) as first-line pharmacologic therapy if treatment is indicated 7
- Monitor for fluid overload without using furosemide - manage with fluid restriction to 80% of basal metabolic requirements if needed 8
- If diuresis is absolutely necessary for heart failure symptoms unrelated to PDA, consider alternative diuretics (thiazides) rather than furosemide, though evidence is limited in this population
Additional FDA Warnings for Premature Infants
Beyond PDA concerns, furosemide in premature infants:
- May precipitate nephrocalcinosis/nephrolithiasis, requiring renal ultrasonography monitoring 1
- Requires careful monitoring of electrolytes, particularly potassium, sodium, calcium, and magnesium 1
- Can cause ototoxicity, especially at doses exceeding 1 mg/kg/24 hours in infants with post-conceptual age <31 weeks 1
Common Pitfall to Avoid
The most dangerous misconception is that furosemide will help manage fluid overload in infants with PDA or reduce indomethacin's renal toxicity. This is false. Furosemide paradoxically worsens both the PDA (by increasing prostaglandin E2) and renal function (by causing acute renal failure and electrolyte derangements) 5, 3, 6.